TLDR: The legal landscape in 2025 is marked by a significant increase in litigation, particularly concerning artificial intelligence business solutions, issues arising from drug trials, and allegations of price-fixing in various sectors. Companies are facing heightened scrutiny and a complex web of legal challenges.
The year 2025 is witnessing a notable surge in litigation across several key areas, with artificial intelligence (AI) business solutions, pharmaceutical drug trial irregularities, and alleged price-fixing schemes emerging as prominent drivers of legal action. This trend underscores an increasingly complex legal environment for businesses.
The AI Litigation Wave:
The rapid adoption of AI technologies has opened a new frontier for legal disputes. Companies are grappling with lawsuits related to AI bias in hiring practices, intellectual property infringements involving AI-generated content, liability questions surrounding automated decision-making processes, and data privacy violations stemming from AI operations. Experts emphasize the critical need for enhanced due diligence, robust compliance programs, and specialized legal expertise to navigate this evolving regulatory landscape. Businesses are advised to collaborate closely with legal counsel to ensure proper management and monitoring of new AI programs and implementations within existing systems to mitigate litigation risks. Furthermore, a noticeable trend in securities litigation involves ‘AI washing’ claims, where companies are accused of overstating their AI capabilities, leading to investor lawsuits when these capabilities fail to meet expectations. For instance, a company that rebranded to focus on AI-powered tools faced a lawsuit after reporting poor quarterly results, and a data management firm was sued following a short-seller report alleging its AI initiatives were ‘smoke and mirrors’.
Drug Trial Miscues and Mass Torts:
The pharmaceutical sector continues to be a significant source of litigation. The plaintiff bar is actively developing the next generation of mass torts, with cases involving allegedly defective earplugs and social media addictions driving the growth of federal court MDL dockets. While specific details on ‘drug trial miscues’ from the provided search results are limited, the broader context of product liability and mass torts suggests ongoing legal challenges in the pharmaceutical and medical device industries. For example, a class action lawsuit against Biogen, Inc. alleging antitrust violations related to generic drug promotion was dismissed in June 2025.
Sporting Goods and Other Price Fixing Allegations:
Also Read:
- AI Firm Perplexity Faces Trademark Challenges, Including ‘Comet’ Browser Launch Dispute
- Businesses Face Significant Risks by Overlooking Generative AI Adoption
Price-fixing allegations are also contributing to the rise in litigation. While the original prompt specifically mentioned ‘sporting goods price fixing,’ the search results provided broader examples of alleged price-fixing. For instance, Kentucky filed a lawsuit in July 2025 against property management software company RealPage Inc. and various landlords, accusing them of engaging in a rent price-fixing scheme using RealPage’s Revenue Management Solutions software. The Department of Justice (DOJ) has also been active in antitrust enforcement, settling a merger challenge between Hewlett Packard Enterprise (HPE) and Juniper Networks in June 2025, which included a requirement for AI source code licensing to preserve competition. This indicates a continued focus by regulatory bodies on maintaining fair competition across various industries, including those impacted by technological advancements.
